Metastatic Cancer clinical trials at UCSF
1 in progress, 1 open to new patients
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
open to eligible people ages 18 years and up
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
San Francisco, California and other locations